Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- US Sales of Prograf Down 17.6% Following Generic Entry
February 15, 2010
- Bendamustine Approved in Singapore: SymBio
February 15, 2010
- Kowa to Launch Livalo Soon in the US
February 15, 2010
- Banyu, Schering-Plough Copromote Mutual Products to Offer New Options for Asthma, Allergy
February 15, 2010
- Astellas to Enter PII for Antibody Drug for Ovarian Cancer
February 15, 2010
- Novartis Aims to Become Top-3 Oncology Company in Japan
February 15, 2010
- Daiichi Sankyo Begins Global PIII Trial for Edoxaban for Prevention of VTE
February 15, 2010
- NBI Aims at RLS to Account for 15% of BI-Sifrol Sales
February 15, 2010
- Application for Eritoran Postponed: Eisai
February 15, 2010
- Taiho to Promote Aloxi with 800 MRs
February 15, 2010
- FUJIFILM to Embark on Generic Business
February 15, 2010
- IHI, UMN Pharma to Create Joint Venture for Flu Vaccines
February 15, 2010
- Fuji Pharma, Mochida to Jointly Develop G-CSF Biosimilar
February 15, 2010
- QOL, Growell, Medipal to Operate Pharmacies for Elderly Consumers
February 15, 2010
- BioNumerik Initiates Global PIII for Tavocept
February 15, 2010
- Toho, Itochu to Create Joint Venture in China with Local Drug Wholesaler
February 15, 2010
- AnGes Completes Enrollment in PIII Trial for Allovectin-7
February 15, 2010
- Mepact Now Available for Osteosarcoma in the EU: Takeda
February 15, 2010
- SEMINAR
February 15, 2010
- ASKA to Comarket Minclea with Nihon Pharm.
February 15, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…